Heparin-induced thrombocytopenia

Blood Reviews

Volumn 13, Issue 1, 1999, Pages 1-7

  Kaplan, K L ^a   Francis, C W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEPARIN; PADGEM PROTEIN; THROMBOCYTE FACTOR 4;

ARTERY THROMBOSIS; COMPLEX FORMATION; ENDOTHELIUM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

EID: 0032895453     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(99)90018-8     Document Type: Article

References (75)

1. Regclson W. Thrombocytopenic and related physiological effects of heparin and heparinoids: A macromolccular-induced syndrome. In Hematological Reviews, Vol. 1 Ed: J.L. Ambrus. Marcel Dekker, Inc., New York 1968.
2. Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 1989; 58:53 57.
3. Becker PS, Miller VT. Heparin-induced thrombocytopenia. Stroke 1989; 20:1449-1459.
4. Weisman RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958; 76:219 227.
5. Laster J, Silver D. Heparin-coatcd catheters and heparin-induced thrombocytopenia. J Vasc Surg 1988; 7:667 672.
6. Ganzer D, Gutezeit A, Mayer G, Greinacher, A, Eichlcr P. Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II. Zeitschrift for Orthopadie ind Ihre Grenzgebiete 1997; 135:543 549.
7. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
8. Nand S, Wong W. Yuen B, Yetter A, Schmulbach E, Fisher SG. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hemat 1997; 56:12-6.
9. Leroy J, Leclerc MH, Delahousse B et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular-weight heparin (CY216). Semin Thromb Hemost 1985; 11:326-329.
10. Eichinger S, Kyrle PA, Brenner, B et al. Thrombocytopenia associated with low-molecular weight heparin. Lancet 1991; 1:1425-1427.
11. de Raucort E, Vinsonneau KH, Fischer AN, Meyer G. Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with lowmolecular-weight heparin. Blood Coagulation and Fibrinolysis 1996; 7:786-788.
12. Insler SR, Kraenzler EH, Bartholomew JR, Kottke-Marchant K, Lytle B, Starr NJ. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Anesthcsiology 1997; 86:495 498.
13. Kappers-Klunne MC, Boon DMS, Hop WCJ et al. Heparin-induced thrombocytopenia and thrombosis: A prospective analysis of the incidence in patients with heart and cerebral vascular diseases. Br J Haematol 1997; 96:442 446.
14. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502 507.
15. Stanton PE Jr, Evans JR, Lefemme AA et al. While clot syndrome. Southern Med J 1988; 81:616-620.
16. Almeida JI, Coats R, Licm TK, Silver D. Reduced mobidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998; 27:309-314.
17. Rhodes GR, Dison RH, Silver D. Heparin-induced thrombocytopenia with thrombotic and hcmorrhagic manifestations. Surg Gynecol Obstet 1973; 136:409-416.
18. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976; 295:237-241.
19. Green D, Harris K, Reynolds N, Roberts M, Patterson R. Heparin immune thrombocytopenia: evidence for a heparinplalelet complex as the antigenic determinant. J Lab Clin Med 1986; 91:167 175.
20. Amiral J, Bridey F, Dreyfus, M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95 96.
21. Kaplan KL, Broekman MJ, Chernoff, A, Lesnick GR, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979; 53:604-618.
22. Kaplan KL. Platelet alpha-granule secretion. In: Platelet Function and Metabolism. Edited by Holm Holmsen CRC Press, Inc., Boca Raton, 1986 pp 145 162.
23. Dawes J, Smith RC, Pepper, DS. The release, distribution, and clearance of human β-thromboglobulin and platelet factor 4. Thrombosis Research 1978; 12:851-861.
24. Busch G, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thrombosis Research 1980; 19:129 137.
25. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Bio Chem 1976; 251:4273-4282.
26. Medici I, DiMartino A, Cella G, Callegaro L, Prosdocimi M. Improved method for purification of human platelet factor 4 by affinity and ion-exchange chromatography. Thrombosis Research 1989; 54:277-287.
27. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81 88.
28. Kelton J, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patient with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83:3232 3239.
29. George JN, Onofre AR. Human platelet surface binding of endogenous secreted factor VIII-von Willebrand factor and platelet factor 4. Blood 1982; 59:194 197.
30. Capitanio AM, Niewiaroski S, Rucinski B et al. Interaction of platelet factor 4 with human platelets. Biochim Biophys Acta 1985; 839:161 173.
31. Ruoslahti E. Structure and biology of proleoglycans. Ann Rev Cell Biol 1988; 4:229-255.
32. Kolset SO, Gallagher JT. Proteoglycans in haemopoietic cells. Biochim Biophys Acta 1032:191 211.
33. Barber AJ, Kaser-Glanzmann R, Jakabova M, Luscher EF. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta 1972; 286:312 329.
34. Huang SS, Huang JS, Deucl TF. Protcoglycan carrier of human platelet factor 4. Isolation and characterization. J Biol Chem 1982; 257:11546-11550.
35. Schick BP. Platelet proteoglycans and sulfated proteins. In Platelet Immunobiology: Molecular and Clinical Aspects Ed. T.J. Kunicki, J.N. George Lippincolt Philadelphia 1989, pp. 44 62.
36. Miescher P, Micschcr R. Die Sedormid-anaphylaxic. Schweizerisch Medizinische Wochenschrift 1952; 82:1279-1282.
37. Humphrey JH, Jacques RJ. The release of histamine and 5-hydroxytryptamine (serotonin) from platelets by antigen-antibody reactions (in vitro). J Physiol 1955; 128:9-[?].
38. Kelton JG, Sheridan D, Santos, A et al. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988; 72:925 930.
39. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparininduced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73:235 240.
40. Anderson GP. Insights into heparin-induced thrombocytopenia. Br J Haematol 1992; 80:504-508.
41. Rosenfeld SI, Looney RJ, Leddy JP, Phipps DC, Abrahams GN, Anderson CL. Human platelet Fc receptor for immunoglobulin G. J Clin Invest 1985; 73:2317-2322.
42. Rubinstein E, Boucheix C, Worthington RE, Carroll RC. Anti-platelet antibody interactions with Fcγ receptor. Seminars in Thrombosis and Hemostasis 1995; 21:10-22.
43. nk. J Biol Chem 1994; 269:32435 32440.
44. Anderson GP, Anderson CL. Signal transduction by the platelet Fc receptor. Blood 1990; 76:1165 1172.
45. Qi R, Ozaki Y, Kuroda K et al. Differential activation of human platelets induced by Fcγ receptor II cross-linking and by anti-CD9 monoclonal antibody. J Immunol 1996; 157:5638 5645.
46. Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 1975; 45:395 401.
47. Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ. Clinical usefulness of testing for a heparindependent platelet-aggregating factor in patients with suspected heparin-associaled thrombocytopenia. J Lab Clin Med 1984; 103:606 612.
48. Clines DB, Kaywin P, Bina M, Tomaski A, Schreiber AD. Heparin-induced thrombocytopenia. N Engl J Med 1980; 303:788-795.
49. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67:27 30.
50. Blank M, Cines DB, Arepally G, Eldor A, Afek A, Shoenfeld Y. Pathogenicily of human anti-platelet factor 4/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin Exp Immunol 1997; 108:333 339.
51. Warkentin TE, Hayward CPM, Boshkov LK et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocylopenia. Blood 1994; 84:3691-3699.
52. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Eng J Med 1987; 316:581-589.
53. Belizna C, Cohen Tervaert JW. Spwcificity, pathogenicity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum 1997; 27:98 109.
54. de Bandt M, Ollivier V. Meyer O et al. Induction of interleukin-1 and subsequent tissue factor expression by antiproteinase 3 antibodies in human umbilical vein endothelial cells. Arthritis and Rheumatism 1997; 40:2030 2038.
55. Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Path 1993; 99:324 330.
56. Bachelol-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach M, Rendu F. Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79:523 528.
57. Amiral J. Bridey F, Wolf M et al. Antibodies to macromolecular platelet factor 4-heparin complexes in hcparin-induccd thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73:21-28.
58. 14C-serotonin release thrombocytopenia. Am J Clin Path 1995; 104:648-654.
59. Look KA, Sahud M, Flaherty S, Zchnder JL. Heparininduced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbet assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis. Am J Clin Path 1997; 108:78-82.
60. Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95:724-731.
61. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997; 98:648-656.
62. Marker LA, Hunt P, Marzec UM et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87:1844 1844.
63. Boon DMS, Michiels JJ, Stibbe J, van Vliet HHDM, Kappers-Klunne MC. Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet 1994; 344:1296-1297.
64. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Int Med 1997; 127:804-812.
65. Slocum MM, Adams JG Jr, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 1996; 23:839-843.
66. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-561.
67. Wilde MI, Markham A. Orgaran. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. 1997; Drugs 54:903-924.
68. Tardy-Poncet, B. French experience in the use of Orgaran as an alternative antithrombotic treatment for patients with heparin-induced thrombocytopenia. Thromb Haemostas 1997; 78:PS1825, (abstr).
69. Miller L, Niecestro R, Magnani H. Successful cardiopulmonary bypass surgery with Orgaran in patients with heparin induced thrombocytopenia. Thromb Haemost 1997; 78:PS-1824, (abstr).
70. Calligaro KD, Kansgra A, Dougherty MJ, Savarese RP, DcLaurentis DA. Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Annals Vasc Surg 1995; 9:397-400.
71. Schiele F, Vuillemenot A, Kramarz P et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50:20-25.
72. Greinacher A, Volpel H, Potzsch TE, Warkentin TE. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia. Thromb Haemost 1995; 73:1456, (Abstr).
73. Schwarz RP Jr. Update on the clinical development of Novastan* (argatroban): A small molecule direct thrombin inhibitor. In: Zavoico, G. (Ed): Advances in Anticoagulant & Antithrombotic Drugs, IBC Biomedical Library Series, International Business communication. Inc., Southborough, MA, 1996.
74. Becker JC, Hursting MJ, Joffrion JL, Knappenberger GD, Lewis BE, Schwarz RP. Clinical effect of concurrent warfarin on the efficacy of argatroban therapy in heparin-induced thrombocytopenia. Blood 1997; 90:Suppl 1, Abstr 3205.
75. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan* (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Sem Thromb Hemost 1997; 23:197-202.